Published in PLoS One on August 28, 2012
LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status. Front Mol Neurosci (2014) 1.03
Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J Neurochem (2014) 0.95
Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J (2013) 0.94
In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Front Mol Neurosci (2014) 0.85
Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation. J Pharm Biomed Anal (2012) 0.84
Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955. PLoS One (2014) 0.78
Multicolored, Tb³⁺-Based Antibody-Free Detection of Multiple Tyrosine Kinase Activities. Anal Chem (2015) 0.77
Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. Sci Rep (2016) 0.76
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol (2008) 14.74
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J (2010) 2.82
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun (2007) 2.42
Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem J (2009) 2.33
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J (2009) 2.14
Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun (2008) 1.71
Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol (2006) 1.68
The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun (2009) 1.67
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol (2011) 1.42
Identification of the autophosphorylation sites of LRRK2. Biochemistry (2009) 1.39
Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett (2004) 1.39
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29
Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun (2009) 1.21
Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J Biomol Screen (2009) 1.20
LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet (2011) 1.08
A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J Biol Chem (2002) 1.07
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A (2011) 1.05
Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett (2012) 1.02
Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. J Neurochem (2011) 1.00
NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. J Pharmacol Exp Ther (2004) 0.99
High-throughput cellular assays for regulated posttranslational modifications. Anal Biochem (2007) 0.97
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord (2010) 0.96
The diploid genome sequence of an Asian individual. Nature (2008) 46.29
The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76
Biosensing with plasmonic nanosensors. Nat Mater (2008) 12.10
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
Ancient human genome sequence of an extinct Palaeo-Eskimo. Nature (2010) 7.51
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2006) 4.71
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
The cell and molecular basis of mechanical, cold, and inflammatory pain. Science (2008) 3.46
Weight gain in the first week of life and overweight in adulthood: a cohort study of European American subjects fed infant formula. Circulation (2005) 3.28
A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study. Ophthalmology (2012) 3.24
Activation of p53 by MEG3 non-coding RNA. J Biol Chem (2007) 3.07
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis (2011) 2.66
A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation. Nat Immunol (2013) 2.60
Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J (2010) 2.43
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci U S A (2008) 2.36
Genetic variation in SCN10A influences cardiac conduction. Nat Genet (2010) 2.30
Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.28
Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents. Bioorg Med Chem (2010) 2.25
Activation of the indole-3-acetic acid-amido synthetase GH3-8 suppresses expansin expression and promotes salicylate- and jasmonate-independent basal immunity in rice. Plant Cell (2008) 2.19
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J (2009) 2.14
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
H2S generated by heart in rat and its effects on cardiac function. Biochem Biophys Res Commun (2004) 2.11
Dispersive pad site burns with modern radiofrequency ablation equipment. Surg Laparosc Endosc Percutan Tech (2003) 2.09
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron (2011) 2.00
Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun (2004) 1.98
A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal. Liver Int (2013) 1.97
A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin beta4 in H322 lung carcinoma cells. Eur J Med Chem (2010) 1.94
Coupling of cell migration with neurogenesis by proneural bHLH factors. Proc Natl Acad Sci U S A (2006) 1.87
MicroRNA-204/211 alters epithelial physiology. FASEB J (2010) 1.83
The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry (2007) 1.81
Controlled plasmonic nanostructures for surface-enhanced spectroscopy and sensing. Acc Chem Res (2008) 1.79
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Generation of genetically modified mice by oocyte injection of androgenetic haploid embryonic stem cells. Cell (2012) 1.72
Compact high-quality CdSe-CdS core-shell nanocrystals with narrow emission linewidths and suppressed blinking. Nat Mater (2013) 1.71
Diagnostic performance of urea breath test, rapid urea test, and histology for Helicobacter pylori infection in patients with partial gastrectomy: a meta-analysis. J Clin Gastroenterol (2012) 1.61
Hyphal growth patterns and recurrence of fungal keratitis after lamellar keratoplasty. Ophthalmology (2007) 1.54
Selective fluorescent probes for live-cell monitoring of sulphide. Nat Commun (2011) 1.51
Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg (2010) 1.51
Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A (2007) 1.49
Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg (2010) 1.47
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Cancer (2010) 1.46
Ultrastable substrates for surface-enhanced Raman spectroscopy: Al2O3 overlayers fabricated by atomic layer deposition yield improved anthrax biomarker detection. J Am Chem Soc (2006) 1.46
Early warning of cotton bollworm resistance associated with intensive planting of Bt cotton in China. PLoS One (2011) 1.46
A survivin double point mutant has potent inhibitory effect on the growth of hepatocellular cancer cells. Cancer Biol Ther (2008) 1.45
Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther (2006) 1.44
Heat shock protein 70 silencing enhances apoptosis inducing factor-mediated cell death in hepatocellular carcinoma HepG2 cells. Cancer Biol Ther (2009) 1.44
Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling. Stem Cells Dev (2010) 1.44
Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol (2008) 1.43
A cross-sectional survey of participation of asthmatic children in physical activity. World J Pediatr (2010) 1.43
CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat (2011) 1.43
Depression recognition using resting-state and event-related fMRI signals. Magn Reson Imaging (2012) 1.41
MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting β-catenin. Biochem Biophys Res Commun (2012) 1.40
Noncompaction cardiomyopathy associated with hypogenetic lung. Chin Med J (Engl) (2007) 1.39
In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J Appl Toxicol (2009) 1.38
Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration (2012) 1.38
Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One (2010) 1.36
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother (2012) 1.36
MicroRNA-10b targets E-cadherin and modulates breast cancer metastasis. Med Sci Monit (2012) 1.35
Translocation of PKC[theta] in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. J Cell Biol (2002) 1.35
Mammalian tissues defective in nonsense-mediated mRNA decay display highly aberrant splicing patterns. Genome Biol (2012) 1.34
The expression pattern of a rice disease resistance gene xa3/xa26 is differentially regulated by the genetic backgrounds and developmental stages that influence its function. Genetics (2007) 1.33
Identification of reference genes for reverse transcription quantitative real-time PCR normalization in pepper (Capsicum annuum L.). Biochem Biophys Res Commun (2011) 1.31
The bHLH transcription factor MdbHLH3 promotes anthocyanin accumulation and fruit colouration in response to low temperature in apples. Plant Cell Environ (2012) 1.30
Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer (2011) 1.29
Diverse genetic basis of field-evolved resistance to Bt cotton in cotton bollworm from China. Proc Natl Acad Sci U S A (2012) 1.28
High genome heterozygosity and endemic genetic recombination in the wheat stripe rust fungus. Nat Commun (2013) 1.28
Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy. Anal Chem (2009) 1.28
SWAP-70-like adapter of T cells, an adapter protein that regulates early TCR-initiated signaling in Th2 lineage cells. Immunity (2003) 1.26
A soybean β-expansin gene GmEXPB2 intrinsically involved in root system architecture responses to abiotic stresses. Plant J (2011) 1.25
Detection of the TCDD binding-fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis. Biochemistry (2009) 1.23
Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats. Amino Acids (2007) 1.23
Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell (2010) 1.23
MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett (2012) 1.22
Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J (2006) 1.22
Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3K/Akt/NF-kappaB pathways. J Neuroimmunol (2006) 1.22
HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 1.22
Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity. Biochem Biophys Res Commun (2009) 1.21
Multiple death pathways in TNF-treated fibroblasts: RIP3- and RIP1-dependent and independent routes. Cell Res (2011) 1.20
Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform. J Biomol Screen (2009) 1.20
MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci (2013) 1.18
Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol (2011) 1.18
Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics (2010) 1.17
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr (2010) 1.17
Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol (2003) 1.17
TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells. Open Biol (2012) 1.16
Hydrogen sulfide derived from periadventitial adipose tissue is a vasodilator. J Hypertens (2009) 1.15
Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med (2012) 1.14
Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection. Am J Physiol Renal Physiol (2010) 1.13
Altered expression of miRNA-21 and its targets in the hippocampus after traumatic brain injury. J Neurosci Res (2010) 1.12
Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Exp Neurol (2008) 1.11
Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One (2011) 1.10
Reorganization of specific chromosomal domains and activation of silent genes in plant cells acquiring pluripotentiality. Dev Dyn (2004) 1.10